Cervical carcinoma in situ is an ideal human research model for experimental immunotherapy because of slow evolution over several years and because spontaneous regression is rare if treatment is withheld. Exfoliative cytology provides a means of precision control to assure safety and to evaluate cell changes compared before, during and after treatment. This long-term report on a small but significant group of 14 cervical cancers (stage 0) treated with a coupled tumor protein antigen produced some regressive cell alterations in all 14 patients and total regression in 5. None of those treated showed progression and there was no evidence of toxicity to kidneys, liver or blood observed. Lymphocytosis (30–60%) was noted during tumor antigen administration. Photomicrographs illustrating the manifestations of cell-mediated immune reaction demonstrate possible mechanisms of tumor cell regression.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً